Suvretta Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Suvretta Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-122,994	Closed	-$9.6M	–	141
2021 Q2	$9.6M	Buy	+122,994	New	+$9.09M	0.14%	82
2020 Q4	–	Sell	-79,331	Closed	-$6.93M	–	133
2020 Q3	$6.93M	Buy	79,331 +54,100	+214%	+$3.77M	0.12%	61
2020 Q2	$1.63M	Sell	25,231 -7,069	-22%	-$408K	0.04%	76
2020 Q1	$1.44M	Buy	+32,300	New	+$1.72M	0.04%	43

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Suvretta Capital Management's TPTX Position: Q3 2021 in Review

Suvretta Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2021, closing a stake of 122,994 shares — an estimated $9.6M sold.

Suvretta Capital Management first reported a position in TPTX in Q1 2020 and held it in 4 quarters. The position peaked at $9.6M in Q2 2021. 190 funds tracked by Wall St. Rank hold TPTX as of Q3 2021.

Suvretta Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Suvretta Capital Management sold 122,994 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $9.6M.
Suvretta Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 4 quarters.
Suvretta Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $9.6M in Q2 2021.
190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Suvretta Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.